
BBRRF does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for BBRRF and 80,000+ other tickers.
See exactly how BBRRF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BBRRF and 80,000+ other tickers.
Blueberries Medical Corp. conducts comprehensive operations in Colombia, covering the entire process of medicinal cannabis and its derivative products—from their initial cultivation and development to final production and distribution. The company specializes in providing pharmaceutical-grade cannabis oil extracts along with other associated therapeutic products. Its corporate headquarters are situated in Bogotá, Colombia.

TORONTO, ON / ACCESS Newswire / August 26, 2026 / Blueberries Medical Corp. (CSE:BBM)(OTCID:BBRRF)(FRA:1OA) (the "Company" or "Blueberries"), a consumer science company focused on health, wellness and longevity, and a licensed producer of both psychoactive and non-psychoactive cannabis derivatives in Colombia, announces a non-brokered private placement consisting of the sale of 84,615,385 common shares ("Common Shares") at a price of C$0.013 per Common Share for aggregate gross proceeds of approximately C$1,100,000 (or approximately US$781,000) (the "Offering"). The net proceeds from the sale of the Common Shares are expected to fund and expand operations, for general corporate and working capital purposes.

TORONTO, ON / ACCESS Newswire / July 29, 2026 / Blueberries Medical Corp. (CSE:BBM)(OTCID:BBRRF)(FRA:1OA) (the "Company" or "Blueberries"), a consumer science company focused on health, wellness and longevity, and a licensed producer of both psychoactive and non-psychoactive cannabis derivatives in Colombia, is pleased to announce a non-brokered private placement consisting of the sale of 84,615,385 common shares ("Common Shares") at a price of C$0.013 per Common Share for aggregate gross proceeds of approximately C$1.1 million (or approximately US$781,000) (the "Offering"). The net proceeds from the sale of the Common Shares are expected to fund and expand operations, for general corporate and working capital purposes.

TORONTO, March 25, 2025 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the "Company" or "Blueberries"), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce a non-brokered private placement consisting of the sale of 96,064,935 common shares ("Common Shares") at a price of C$0.011 per Common Share for aggregate gross proceeds of approximately C$1.05 million (or approximately US$740,000) (the "Offering"). The net proceeds from the sale of the Common Shares are expected to fund and expand operations, for general corporate and working capital purposes. The Offering is expected to close on or about March 25, 2025.

TORONTO, March 07, 2025 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the “Company” or "Blueberries"), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce a non-brokered private placement consisting of the sale of 96,064,935 common shares (“Common Shares”) at a price of C$0.011 per Common Share for aggregate gross proceeds of approximately C$1.05 million (or approximately US$740,000) (the “Offering”). The net proceeds from the sale of the Common Shares are expected to fund and expand operations, for general corporate and working capital purposes. The Offering is expected to close on or about March 25, 2024.

TORONTO, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the “Company” or "Blueberries"), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, announces a non-brokered private placement consisting of the sale of 180,716,00 common shares (“Common Shares”) at a price of C$0.011 per Common Share for aggregate gross proceeds of approximately C$1,987,876 (or approximately US$1,250,000) (the “Offering”). The net proceeds from the sale of the Common Shares will be used to repay existing debt and for general corporate and working capital purposes.